ELI-005

**ELI-005** is an investigational lymph node-targeted SARS-CoV-2 protein-subunit vaccine developed by Elicio Therapeutics. It combines SARS-CoV-2 spike receptor-binding-domain protein with AMP-CpG, a diacyl lipid-modified CpG7909 Toll-like receptor 9 agonist adjuvant designed to bind endogenous albumin after subcutaneous injection and traffic to draining lymph nodes. Lymph-node delivery promotes antigen-presenting-cell activation, spike-specific neutralizing antibody production, and cellular T-cell responses; published preclinical studies in mice and non-human primates reported cross-reactive responses against multiple SARS-CoV-2 variants. ([nature.com](https://www.nature.com/articles/s41541-022-00560-3))